UK Markets closed

Is Merck's Planned Acquisition of Acceleron in Trouble?

·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Merck's move doesn't mean that the acquisition of Acceleron is in trouble.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting